InterCure Ltd. (INCR)
Official siteHEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ
Market Cap: $49.17M
Last updated: Nov 17, 2026 at 10:48 AM ET
InterCure Ltd. (INCR) Financials: Revenue, Profit and Cash Flow
InterCure reported revenue of ILS 270.20M for the fiscal year ended Dec 31, 2025, up 13.1% from the year before. That year, net income was ILS -35.71M with a net margin of -13.2%, operating cash flow was ILS 16.84M and free cash flow was ILS 13.29M. The quarter ended Mar 31, 2026 had revenue of ILS 70.09M and net income of ILS -17.00M.
Revenue and Margins
The operating margin was 2.5% in the fiscal year ended Dec 2025. Over the 6 years to Dec 2025, revenue grew from ILS 8.93M, a compound annual rate of 76.5%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | 270.20M | +13.1% | 12.3% | 2.5% | -13.2% |
| Dec 2024 | 238.84M | -32.8% | 12.7% | -28.1% | -28.4% |
| Dec 2023 | 355.55M | -8.5% | 29.6% | -11.7% | -17.4% |
| Dec 2022 | 388.68M | +76.9% | 39.9% | 13.0% | 11.5% |
| Dec 2021 | 219.68M | +237.8% | 41.5% | 12.8% | 2.1% |
| Dec 2020 | 65.03M | +628.6% | 49.2% | -59.0% | -57.2% |
| Dec 2019 | 8.93M | N/A | 16.6% | -38.3% | -66.0% |
| Dec 2018 | 0 | N/A | N/A | N/A | N/A |
| Dec 2017 | 0 | N/A | N/A | N/A | N/A |
| Dec 2016 | N/A | N/A | N/A | N/A | N/A |
Income Statement
In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Mar 2026, the net loss widened from the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 270.20M | 238.84M | 355.55M | 388.68M | 219.68M | 65.03M | 8.93M | 0 | 0 | N/A |
| Cost of revenue | 237.02M | 208.61M | 250.46M | 233.60M | 128.55M | 33.06M | 7.45M | N/A | 0 | N/A |
| Gross profit | 33.18M | 30.23M | 105.09M | 155.08M | 91.13M | 31.98M | 1.48M | N/A | 0 | N/A |
| Research and development | 390.00K | 414.00K | 388.00K | 632.00K | 1.24M | 1.58M | 1.71M | 0 | 0 | 0 |
| Operating income | 6.73M | -67.21M | -41.57M | 50.63M | 28.19M | -38.40M | -3.42M | -10.62M | -3.98M | 1.20M |
| Net income | -35.71M | -67.80M | -61.96M | 44.82M | 4.69M | -37.23M | -5.89M | -12.80M | -5.26M | 265.42K |
| EBITDA | N/A | -51.31M | -23.90M | 70.23M | 31.17M | -34.53M | N/A | -10.12M | -1.15M | N/A |
Quarterly
| Line item | Mar 2026 | Sep 2025 | Jun 2025 | Mar 2025 | Sep 2024 | Jun 2024 | Mar 2024 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 70.09M | 70.09M | 65.01M | 65.01M | 56.56M | 62.87M | 62.87M | 73.47M | 102.44M | 106.17M | 105.61M | 100.57M |
| Gross profit | 239.50K | 239.50K | 20.11M | 20.11M | 195.50K | 20.83M | 20.83M | 18.16M | 32.64M | 34.33M | 25.86M | 46.21M |
| Operating income | -16.48M | -16.48M | 2.86M | 2.86M | -38.86M | 5.26M | 5.26M | -26.67M | 5.82M | 5.95M | -1.57M | 16.18M |
| Net income | -17.00M | -17.00M | -852.00K | -852.00K | -34.61M | 716.50K | 716.50K | -33.53M | 4.88M | 214.00K | 5.27M | 7.26M |
Balance Sheet
As of Dec 2025, total debt of ILS 163.52M exceeded cash and equivalents by 117.06M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 690.55M | 762.57M | 786.61M | 958.01M | 686.32M | 326.27M | 282.23M | 35.92M | 23.95M | 27.73M |
| Current assets | 316.75M | 391.80M | 418.80M | 527.49M | 336.16M | 76.65M | 42.21M | 4.96M | 2.48M | 3.28M |
| Cash and equivalents | 46.47M | 78.32M | 101.14M | 232.59M | 196.22M | 37.89M | 27.34M | 3.42M | 2.12M | 2.80M |
| Total liabilities | 294.19M | 364.90M | 329.55M | 436.53M | 227.13M | 34.16M | 26.03M | 16.26M | 3.27M | 3.67M |
| Short-term debt | 104.06M | 74.22M | 92.83M | 132.37M | 75.59M | 2.55M | 13.85M | 12.78M | 2.94M | 2.39M |
| Long-term debt | 59.46M | 113.98M | 82.20M | 99.68M | 11.95M | 629.00K | 436.00K | N/A | N/A | N/A |
| Shareholder equity | 396.52M | 396.97M | 455.11M | 501.31M | 448.03M | 274.51M | 255.97M | 19.66M | 20.68M | 24.07M |
Quarterly
| Line item | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 690.55M | 690.55M | 690.55M | 751.76M | 751.76M | 762.57M | 762.57M | 740.89M | 740.89M | 786.61M | 786.61M | 841.85M |
| Total liabilities | 294.19M | 294.19M | 294.19M | 319.52M | 319.52M | 364.90M | 364.90M | 278.77M | 278.77M | 329.55M | 329.55M | 314.19M |
| Cash and equivalents | 46.47M | 46.47M | 46.47M | 51.33M | 51.33M | 78.32M | 78.65M | 19.90M | 19.90M | 101.14M | 101.14M | 102.65M |
| Shareholder equity | 396.52M | 396.52M | 396.52M | 431.15M | 431.15M | 396.97M | 396.97M | 460.44M | 460.44M | 455.11M | 455.11M | 508.76M |
Cash Flow
In the fiscal year ended Dec 2025, free cash flow was 78.9% of operating cash flow.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 16.84M | -66.93M | -53.63M | 51.27M | 25.02M | 7.80M | -4.01M | -1.49M | -921.03K | N/A |
| Capital expenditures | 3.55M | 4.38M | 2.62M | 19.74M | 14.03M | 20.84M | 1.00K | 93.00K | 93.00K | N/A |
| Free cash flow | 13.29M | -71.30M | -56.25M | 31.52M | 10.99M | -13.04M | -4.01M | -1.58M | -1.01M | N/A |
| Investing cash flow | -1.99M | 17.69M | 4.77M | -142.50M | -65.21M | -22.76M | -38.54M | -7.96M | -2.26M | N/A |
| Financing cash flow | -46.66M | 26.45M | -82.89M | 120.45M | 197.94M | 25.29M | 66.17M | 10.61M | 2.86M | 12.27M |
Quarterly
| Line item | Mar 2026 | Sep 2025 | Jun 2025 | Mar 2025 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 16.84M | 2.32M | 6.10M | 6.10M | N/A | -21.74M | -21.74M | N/A | N/A | 949.00K | -52.54M | 43.16M |
| Capital expenditures | 3.55M | 152.00K | 1.62M | 1.62M | 0 | 178.00K | 178.00K | 0 | 0 | 3.81K | 688.00K | 4.68M |
| Free cash flow | 13.29M | 2.17M | 4.48M | 4.48M | N/A | -21.92M | -21.92M | N/A | N/A | 945.19K | -53.23M | 38.48M |
Frequently Asked Questions About INCR
What is InterCure's annual revenue?
InterCure reported revenue of ILS 270.20M for the fiscal year ended Dec 31, 2025.
How fast is InterCure's revenue growing?
Revenue was up 13.1% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was -11.4%.
Is InterCure profitable?
No. InterCure reported net income of ILS -35.71M for the fiscal year ended Dec 31, 2025, with a net margin of -13.2%.
How much free cash flow does INCR generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of ILS 16.84M minus capital expenditures of ILS 3.55M produced free cash flow of ILS 13.29M.
How much debt does InterCure have?
The balance sheet dated Dec 31, 2025 reported long-term debt of ILS 59.46M, short-term debt of ILS 104.06M and cash and equivalents of ILS 46.47M.
INCR pages: Overview, Financials